McKesson: Immune To Weak Economy And Tariffs; Top Idea In 2025

Core Viewpoint - McKesson (NYSE: MCK) has shown strong performance in the oncology sector, leading to a significant outperformance of its stock price compared to the market since November 2024 [1]. Group 1 - The company has a robust oncology network that contributes to its superior growth, even in a challenging macroeconomic environment [1]. - The stock has been rated as a 'Strong Buy' due to its performance and growth potential [1].